Epifix denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epifix are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied EpiFix: Not FDA-Approved

EpiFix is marketed as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) regulated under FDA Section 361 of the Public Health Service Act. Under that regulatory pathway, qualifying tissue products are not required to obtain pre-market approval (PMA) or 510(k) clearance in the same way as drugs or devices — they are regulated for safety and processing standards rather than efficacy via a formal approval. A "not FDA-approved" denial from BCBS likely reflects either a misapplication of drug-approval standards to a tissue product, or a plan policy that requires FDA marketing approval (rather than Section 361 HCT/P registration) as a coverage prerequisite.

## Why This Denial Is Appealable

The regulatory framework for tissue allografts like EpiFix is distinct from the pharmaceutical approval pathway, and conflating the two is a basis for appeal. Your appeal should document EpiFix's regulatory status under the applicable FDA framework, and your prescriber can address how EpiFix is used consistent with its cleared or registered status. If BCBS's policy requires a specific type of FDA clearance, the appeal should also address whether EpiFix meets that standard under the correct regulatory category.

## Your Federal Appeal Rights

• Internal appeal: Under ACA Section 2719 and ERISA Section 503, you are entitled to a full-and-fair internal review. File within the deadline in your denial letter.
• External review: If the internal appeal is denied, escalate to an Independent Review Organization (IRO) within approximately four months of exhausting internal remedies. IROs apply independent clinical and regulatory standards, not BCBS's internal policy definitions.
• Expedited review: Request expedited processing if your wound presents an urgent or limb-threatening condition.

## Documentation to Gather

• EpiFix regulatory documentation: Obtain documentation from the manufacturer regarding EpiFix's FDA regulatory status under the applicable HCT/P framework (Section 361). This directly rebuts the "not FDA-approved" characterization.
• Prescriber letter addressing regulatory status: A letter from your wound care specialist or prescriber explaining EpiFix's regulatory classification and how it is used within that classification.
• Wound diagnosis and treatment history: Records documenting your wound type, severity, duration, and prior treatment history with dates and outcomes.
• BCBS policy clarification: Request BCBS's written explanation of exactly what type of FDA authorization their policy requires, so your appeal can address the specific policy language.

## Criteria-Mapping Structure

Request the exact language from BCBS's medical or coverage policy that defines the FDA-authorization requirement they applied. Address each element:

| Denial Basis | Your Rebuttal Evidence | |---|---| | "Not FDA-approved" characterization | Manufacturer documentation of EpiFix's FDA regulatory status under HCT/P framework | | Policy's specific FDA-authorization requirement | Side-by-side comparison of policy language vs. EpiFix's regulatory classification | | Medical necessity of EpiFix | Prescriber medical-necessity letter with wound documentation |

For external review, ask the IRO to evaluate whether BCBS's policy definition of "FDA-approved" is consistent with the applicable regulatory framework for human tissue products.